On September 19, 2015, Zhang Tingdong, an 83-year-old tenured professor at the First Hospital affiliated with Harbin Medical University, was honored with this year’s Distinguished Scientist Award for his ground-breaking contribution to the treatment of leukemia with arsenic trioxide (ARsenic trioxide, ATO) in Hefei, Anhui Province. The announcement of this award, so that the public’s attention once again focused on the magic of Chinese medicine cream!
Professor Zhou Jin, an expert in hematology at the University of Kazakhstan, congratulated Professor Zhang Tingdong, who was awarded the Distinguished Scientist Award by the Foundation for Science and Technology.
Zhang Tingdong, a tenured professor at ha medical university, delivered a speech.
Zhang Tingdong and arsenic trioxide treatment of leukemia The magic charm of Chinese medicine has attracted worldwide attention.
In the late autumn of 1971, Heilongjiang Provincial Office of Cancer Prevention and Control received a response: the province’s Lindian County Democratic Commune Health Hospital using toxic drugs to treat malignant tumors, because the effect is very good to attract many patients to seek treatment. At that time, the province’s health system is extensive excavation, collection, sorting anti-cancer Chinese medicine and folk testing, secret work. Upon learning of this news, Professor Zhang Tingdong, chairman of the Association of Chinese and Western Medicine in Heilongjiang Province and former director of the Chinese Medicine Department of the University of Kazakhstan, was appointed as the head of the expert group and took the team to “explore the wind” to understand the truth.
Professor Zhang Tingdong led a team of experts came to the Lindian County Democratic Commune, found that there are no medical equipment, but there are indeed many patients, after understanding that, after understanding, an old Chinese medicine in the countryside here has a secret recipe, is the use of Chinese medicine cream, light powder, A few tastes of highly toxic materials prepared, originally used to cure rat sores – lymph gland tuberculosis, and later by a pharmacist with this medicine to cure his mother’s skin cancer after the change into a needle intramuscular injection to treat a variety of cancers. The agent was named “713”. Professor Zhang Tingdong checked the patient’s condition one by one, asked about the effect of their medication, found that the secretion of uterine cancer patients after drug use significantly reduced, liver cancer patients after medication pain disappeared. Another esophageal cancer patient recognized the group of experts Professor Zhao, a few years ago, he looked for Professor Zhao to see the disease, but because the disease is too serious can not be cured, then returned home, heard that this medicine, dead horse when the live horse doctor to try, the result of the drug can not only drink water, but also eat, walk. Professor Zhao confirmed the change after his recollection, and thought the change was really amazing. Professor Zhang Tingdong immediately took the patient to the county hospital for a perspective to see how his esoptopathy had changed. Results came out, found that the patient’s esopathy has a gap, the degree of stenosis has been significantly improved, this is really amazing, it seems that this “713” is really effective!
Zhang Tingdong is a combination of Chinese and Western medicine hematologists, would like to open the gap in “blood cancer”. After returning from the countryside, he began to divide the original side into two groups to do in-body tumor suppression test, one group consists of frost, light powder, the other group is composed of frost, frost, ” named “Cancer Spirit 1, 2” injection. Observations found that both groups of drugs are effective, but the former continuous drug often appear proteinuria, indicating damage to the kidneys, because light powder is mercury, affecting kidney function, so remove light powder; A single left frost, there is still a significant role.
The main components of arsenic trioxide or sub-arsenic acid are highly toxic. People use it to treat asthma, external treatment of sores, stubborn, but all generations of doctors to enable frost, are cautious. With the cooperation and help of the late Korean pharmacist Han Taiyun, Zhang Tingdong’s team made bold innovations to purified the cream and eventually refined it into a sub-arsenic acid injection.
In 1974, Dong Xiuzhi, a 22-year-old female worker, became one of the early beneficiaries of arsenic injections. She was 7 months pregnant, was knocked down by a sudden disease: bleeding in the mouth, bleeding in the nose, even in the urine is blood, skin color like white paper. After being sent to the hospital, he was diagnosed with acute early granulocytic leukemia (M3 type), and the child miscarried the next day after being admitted to the hospital. But after four months of silence, she had a miracle. Xiao Dong, who couldn’t even turn over, slowly stood up and was able to walk down the ground. At the end of the same year, Xiao Dong was discharged from the hospital and went home, taking medicine, dripping and reviewing according to the doctor’s orders. She became pregnant again in 1976 and gave birth to a boy, returning to work in 1979. I’ve been safe and sound until now.
Leukemia is commonly known as “blood cancer” and has a high mortality rate among children and adolescents. Among them, acute early granulocytic leukemia (M3 type) is an acute granulocytic leukemia with special chromosomal abnormalities, clinically characterized by acute illness, dangerous illness, short course of illness, easy infection, easy to accompany diffuse vascular clotting (DIC), and intense chemotherapy often induces DIC exacerbation and death.
Experts in Shanghai have found that arsenic has an induced differentiation effect on acute early granulocytes and causes cancer cells to apoptosis, even as they move toward a “suicide” path to programmed death. Happily, in 1999, Ida Pharmaceutical Co., D.C., obtained a national invention patent with a patent term of 20 years, and in the second half of the same year, the drug was approved as a class II new drug by the State Drug and Food Administration. In September 2000, the FDA approved the clinical use of arsenicate.
The clinical exploration of arsenic drug use has always advanced in depth, and the scientific exploration is never-ending. As the origin of arsenic treatment of leukemia, the doctors of the First Hospital of Ha Medical University passed on from generation to generation, and the “baton” of frost research continued step by step.
With a large number of M3 leukemia patients from all over the country flocked to the haematology ward of haematology hospital, the Chinese Physicians Association hematologist branch standing committee member, Heilongjiang Provincial Medical Association hematology professional committee chairman, haematology director Professor Zhou Jin found that some patients in the clinical application of arsenic acid injection after abnormal increase in intravascular white blood cells, which is easy to aggravate diffuse intravascular clotting, easy to merge intracranial bleeding, and finally life-threatening. To this end, Professor Zhou’s research team continued to explore, successfully established a continuous slow intravenous infusion of arsenic acid and its mathematical model, and then accurately controlled the speed of intravenous infusion of arsenicate and the amount of medication, to a large extent corrected the use of arsenic trioxide regular static point when the high rate of “high white blood disease”, reducing the fatal cerebrovascular events and adverse reactions. Professor Zhou Jin’s invention was awarded the first prize of scientific and technological progress by the Ministry of Education in 2004. At the same time, the team also pioneered the discovery of arsenic trioxide on myocardial potassium, calcium ion channels, intracellular calcium and its effect mechanism on cell membrane ion channels and intracellular calcium, and scientifically revealed the molecular pharmacological mysteries of arsenic trioxide leading to the extension of the Q-T period of the heart and the root causes of adverse effects on the heart.
At the same time, Another topic led by Professor Zhou Jin, “Research on the Single Application of Arsenic Acid for the Treatment of Acute Early Granulocytic Leukemia in Primary Children”, was published in full in English in the internationally renowned journal Blood in March 2010. Previous studies have shown that subarric acid alone can significantly alleviate acute early granulocytic leukemia in primary adults, but it is little known whether it is effective in children, and it is not clear whether the children’s reasonable dosage, route of medication and hematology completely alleviated rate, long-term drug use effect and related toxicity, safety and other issues are unknown. Professor Zhou’s team gave the answer that the single use of sub-arsenic acid can make the overall survival rate of M3 leukemia in children for 5 years and disease-free survival rate of 83.9% and 72.2%, respectively, with the currently recognized efficacy of the anti-cyclic antibiotic program, and there is no obvious risk of chronic arsenic poisoning and secondary tumors.
In the 2011 Heilongjiang Province Science and Technology Progress Award, Professor Zhou Jin, Director of The Hematology Department of the First Hospital affiliated with Ha Medical University, won the first prize for the completed project “New Discovery and Innovation of Anti-Leukemia Target of Arsenicate Anti-Leukemia”. For the first time, the results “locked” three cell membrane targets (HERG potassium channel, L-type calcium channel, PKC kinase) and one subarric acid mitochondrial gene target (D-LOOP region), which caused sub-arsenic acid Cytoxic damage to arsenicate, which aggravates the adverse stimulation of the cardiovascular system, thus dragging the back legs of the efficacy of sub-arsenicate, is the crux of the adverse reaction of sub-arsenic acid in the treatment of M3 leukemia; The glycol-assisted permeable method under the control of the mathematical model, which enhances the efficacy of anti-leukemia and weakens the toxic damage to normal tissue cells and the effect on myocardial tissue by prolonging the stay of free arsenic in circulating blood and maintaining the lowest effective blood arsenic concentration required for leukemia apoptosis. The latter is the characteristics of easy to pass through the blood-brain barrier with the help of glycol, combined with mathematical model calculation of individualized dose of drug, can significantly improve the content of cerebrospinal fluid Central Asian arsenic, so that it can induce the effective concentration level of leukemia cell differentiation in cerebrospinal fluid, efficient and low-toxic strangulation of central system leukemia. While improving the efficiency of eliminating leukemia cells, the damage to normal cells is reduced, and the purpose of reducing toxicity and expanding the adaptive disorder is achieved. The above two new drug-giving methods showed that the incidence of high lewd cellemia caused by subarric acid decreased by 40%, the early mortality rate caused by secondary cerebrovascular events and diffuse intravascular clotting decreased by 26.7%, and the incidence of long QT syndrome decreased by 34%, of which the incidence of fatal long QT events was zero. In addition, the new method of anti-leukemia direct medical expenses are lower than traditional drug treatment methods, indirect medical expenses to deal with adverse reactions to save about 65%, the rate of initial drug use of acute early granulocytic leukemia to achieve complete remission is 11.5% higher than traditional methods, and the traditional drug effect is not sensitive to some other leukemia subtypes also show positive efficacy.
At present, the hospital is continuing to expand the clinical samples of arsenicate anti-leukemia, its long-term efficacy and long-term prognosis follow-up. At the same time, the hospital has extended this method to the treatment of solid tumors such as persistent infusion in the arteries of cancerous chest water and liver cancer.
Under the leadership of Professor Zhong Jin, the hospital’s hematology department to leukemia M3-type as the main direction of attack, one after another to undertake the National Natural Science Foundation of China 3 projects, provincial and ministerial-level scientific research projects more than 20; Has published more than 60 relevant academic papers at home and abroad, of which SCI included more than 20 articles, the influence factor of up to 10.555. Not only that, the application of arsenic preparations, but also by the Chinese Academy of Sciences “2000 Scientific Development Report” as “the twentieth century China’s top ten scientific and technological inventions”, and in 2008 as Heilongjiang Province, “reform and opening up 30 years of the top ten scientific and technological achievements.”
The use of arsenic preparations has saved the lives of thousands of patients. Six-year-old children from Jiujiang City, Jiangxi Province fruit, a year ago due to oral blood bubbles, gums seepage, nasal bleeding and accompanied by fever and medical treatment, the local children’s hospital diagnosed as acute early granulocytic leukemia with DIC (dispersed blood vessel clotting), by the use of vitamin acid and chemotherapy and other methods of emergency rescue, no signs of improvement; His family rushed him to haematology for medical treatment. After being diagnosed with type M3 leukemia, Director Zhou Jin immediately developed a treatment plan for his child and injected him with sub-arsenic acid. A month later, the little guy finally turned to safety, blood elephant, bone marrow elephant gradually returned to normal. This fall, Xiaoguo has been in the local primary school.
Now, arsenic acid injection has become a hospital affiliated with the first-line drugs and “watch home treasure.” So far, the hospital’s hematology department has treated more than 5000 cases of M3 leukemia in more than 30 provinces across the country, with a complete remission rate of more than 91%. In the long-term follow-up of some patients, it was confirmed that more than 5 years of survival of more than 84%, nearly 1 to 2 have survived more than 10 years. One of the longest survivors has been 37 years, can be called China’s leukemia miracle!